MARKET

IKT

IKT

Inhibikase Therapeutics Inc
NASDAQ
2.080
-0.050
-2.35%
Opening 14:04 04/18 EDT
OPEN
2.102
PREV CLOSE
2.130
HIGH
2.150
LOW
2.044
VOLUME
26.36K
TURNOVER
0
52 WEEK HIGH
4.351
52 WEEK LOW
0.7900
MARKET CAP
13.47M
P/E (TTM)
-0.5829
1D
5D
1M
3M
1Y
5Y
Inhibikase Therapeutics Inc: Other preliminary proxy statements
Press release · 2d ago
Weekly Report: what happened at IKT last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at IKT last week (0401-0405)?
Weekly Report · 04/08 09:46
INHIBIKASE THERAPEUTICS INC - MEETING WILL BE HELD ON APRIL 5, 2024, WITH MEETING RESULTS TO BE REPORTED FOLLOWING RECEIPT OF FORMAL MEETING MINUTES
Reuters · 04/03 12:05
Inhibikase Therapeutics Inc: Initial statement of beneficial ownership of securities
Press release · 04/03 06:14
Buy Rating Affirmed for Inhibikase Therapeutics Amid Clinical Advancements and Regulatory Progress
TipRanks · 04/02 19:15
Weekly Report: what happened at IKT last week (0325-0329)?
Weekly Report · 04/01 09:46
Inhibikase Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Inhibikase Therapeutics Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 64 cents per share. The mean expectation of two analysts was for a loss of 85 cents. Reported revenue was zero; analysts expected zero. Shares had risen by 81.1% this quarter.
Reuters · 03/29 13:31
More
About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate. The Company’s RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.

Webull offers Inhibikase Therapeutics Inc stock information, including NASDAQ: IKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IKT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IKT stock methods without spending real money on the virtual paper trading platform.